Arrowhead Pharmaceuticals - ARWR Stock Forecast, Price & News

Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes ARO-AAT, a RNA interference (RNAi) therapeutic candidate that is in Phase II clinical trial for the treatment of liver diseases associated with alpha-1 antitrypsin deficiency; ARO-APOC3, which is in phase 2b and one phase 3 clinical trial to treat hypertriglyceridemia; ARO-ANG3 that is in Phase 2b clinical trial to reduce production of angiopoietin-like protein 3; ARO-HSD, which is in Phase 1/2a clinical trial to treat liver diseases; ARO-ENaC, which is in a Phase 1/2a clinical trial to reduce production of the epithelial sodium channel alpha subunit in the airways of the lung; ARO-C3 for the treatment of complement-mediated disease that is in Phase 1/2a clinical trial; ARO-Lung2 for the treatment of chronic obstructive pulmonary disorder; ARO-DUX4 for the treatment of facioscapulohumeral muscular dystrophy; ARO-XDH to treat uncontrolled gout; ARO-COV for the treatment of COVID-19 and other pulmonary-borne pathogens; and ARO-HIF2, which is in phase 1b clinical trial to treat clear cell renal cell carcinoma. It is also involved in the development of JNJ-3989, a subcutaneously administered RNAi therapeutic candidate to treat chronic hepatitis B virus infection; Olpasiran to reduce the production of apolipoprotein A; and ARO-AMG1 for treating genetically validated cardiovascular targets. Arrowhead Pharmaceuticals, Inc. has a license and research collaboration agreement with Janssen Pharmaceuticals, Inc. to develop ARO-JNJ1, ARO-JNJ2, and ARO-JNJ3 RNAi therapeutics for liver-expressed targets; and license and research collaboration agreement with Takeda Pharmaceuticals U.S.A., Inc. to develop RNAi therapeutic candidate as a treatment for liver disease. Arrowhead Pharmaceuticals, Inc. was incorporated in 1989 and is headquartered in Pasadena, California.

Arrowhead Pharmaceuticals Stock Down 3.7 %

Shares of Arrowhead Pharmaceuticals stock traded down $1.75 on Wednesday, reaching $45.88. The stock had a trading volume of 457,036 shares, compared to its average volume of 783,829. The company has a 50 day moving average price of $39.14 and a 200 day moving average price of $41.63. The company has a quick ratio of 3.37, a current ratio of 3.37 and a debt-to-equity ratio of 0.16. Arrowhead Pharmaceuticals has a 1 year low of $26.81 and a 1 year high of $84.83. The stock has a market capitalization of $4.86 billion, a P/E ratio of -31.48 and a beta of 1.37.

Arrowhead Pharmaceuticals (NASDAQ:ARWR - Get Rating) last released its earnings results on Thursday, August 4th. The biotechnology company reported ($0.68) EPS for the quarter, missing analysts' consensus estimates of ($0.51) by ($0.17). The company had revenue of $32.41 million during the quarter, compared to analyst estimates of $52.61 million. Arrowhead Pharmaceuticals had a negative return on equity of 36.05% and a negative net margin of 61.58%. The firm's revenue for the quarter was down 29.4% on a year-over-year basis. During the same quarter last year, the business earned ($0.29) earnings per share. As a group, equities research analysts forecast that Arrowhead Pharmaceuticals will post -1.08 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of research firms have commented on ARWR. Chardan Capital raised their target price on shares of Arrowhead Pharmaceuticals from $80.00 to $82.00 in a research report on Friday, August 5th. Robert W. Baird raised shares of Arrowhead Pharmaceuticals from a "neutral" rating to an "outperform" rating and cut their target price for the company from $71.00 to $60.00 in a research report on Wednesday, May 11th. The Goldman Sachs Group raised their target price on shares of Arrowhead Pharmaceuticals from $58.00 to $65.00 and gave the company a "buy" rating in a research report on Monday, August 8th. Piper Sandler cut their target price on shares of Arrowhead Pharmaceuticals from $89.00 to $72.00 in a research report on Wednesday, May 11th. Finally, HC Wainwright reaffirmed a "buy" rating and issued a $110.00 price objective on shares of Arrowhead Pharmaceuticals in a research report on Thursday, July 14th. Two investment analysts have rated the stock with a hold rating and four have assigned a buy rating to the company's stock. Based on data from MarketBeat.com, Arrowhead Pharmaceuticals presently has a consensus rating of "Moderate Buy" and an average price target of $70.83.